Primary Record
latrunculin B
- In stock
- 1,468 g
- Purity
- 98.1 %
- CAS
- 76343-94-7
Compound Identifiers & Properties
- CAS
- 76343-94-7
- PubChem CID
- 6436219
- SMILES
- C[C@H]/1CC[C@@H]2C[C@H](C[C@@](O2)([C@@H]3CSC(=O)N3)O)OC(=O)/C=C(\CC/C=C1)/C
- Canonical SMILES
- C/C1=C/C(=O)O[C@@H]2C[C@@H](CC[C@H](C)/C=C\CC1)O[C@@](O)([C@@H]1CSC(=O)N1)C2
Names & Synonyms
- latrunculin B
- LAT-B
- latrunculin-B
- (+)-latrunculin B
- Lat B
- 76343-94-7
- LATRUNCULINB
- RefChem:152464
- C20H29NO5S
- LW7U308U7U
- UNII-LW7U308U7U
- CHEBI:49703
- D07EHB
- AC1O5L9Q
- LATRUNCULIN B [MI]
- BSPBio_001189
- DTXSID10881387
- NSHPHXHGRHSMIK-JRIKCGFMSA-N
- AC1Q29P5
- CHEMBL411879
- SCHEMBL2531366
- INS-115644
- NSC 339663
- NSC-339663
- BCBcMAP01_000226
- Latrunculin B, Latrunculia magnifica
- INS115644
- DTXCID201022649
- HMS1362K11
- HMS1792K11
- HMS1990K11
- HMS3403K11
- BDA34394
- Latrunculin B from Latruncula magnifica
- ZINC5751767
- C20-H29-N-O5-S
- LAT-B; NSC 339663
- 1814AH
- BDBM50508923
- MFCD00270879
- NSC339663
- AKOS032947159
- CID6436219
- DB08080
- CID:6436219
- IDI1_002180
- SMP2_000317
- NCGC00163459-03
- AS-83262
- DA-49463
- SID:53790712
- HY-101848
- J825.707H
- CS-0022006
- C037068
- A1205017
- Q4255012
- BRD-K30455030-001-03-3
- BRD-K61292460-001-02-3
- (4R)-4-[(1R,4Z,8Z,10S,13R,15R)-15-hydroxy-5,10-dimethyl-3-oxo-2,14-dioxabicyclo[11.3.1]heptadeca-4,8-dien-15-yl]-1,3-thiazolidin-2-one
- 2-Thiazolidinone, 4-(15-hydroxy-5,10-dimethyl-3-oxo-2,14-dioxabicyclo(11.3.1)heptadeca-4,8-dien-15-yl)-, (1R*,4Z,8Z,10S*,13R*,15R*(R*))-(+)-
- Latrunculin B from Latruncula magnifica, >=80% (HPLC), solid
- (4R)-[(1R,4Z,8Z,10S,13R,15R)-15-hydroxy-5,10-dimethyl-3-oxo-2,14-dioxabicyclo[11.3.1]heptadeca-4,8-dien-15-yl]-2-thiazolidinone
- (4R)-4-((1R,4S,5Z,9Z,13R,15R)-15-hydroxy-4,9-dimethyl-11-oxo-12,16-dioxabicyclo(11.3.1)heptadeca-5,9-dien-15-yl)-1,3-thiazolidin-2-one
- (4R)-4-((1R,4Z,8Z,10S,13R,15R)-15-hydroxy-5,10-dimethyl-3-oxo-2,14-dioxabicyclo(11.3.1)heptadeca-4,8-dien-15-yl)-1,3-thiazolidin-2-one
- (4R)-4-[(1R,4S,5Z,9Z,13R,15R)-15-hydroxy-4,9-dimethyl-11-oxo-12,16-dioxabicyclo[11.3.1]heptadeca-5,9-dien-15-yl]-1,3-thiazolidin-2-one
- (4R)-4-[(1R,4S,5Z,9Z,13R,15R)-15-hydroxy-4,9-dimethyl-11-oxo-12,16-dioxabicyclo[11.3.1]heptadeca-5,9-dien-15-yl]thiazolidin-2-one
- (4R)-4-[(1R,4Z,8Z,10S,13R,15R)-15-Hydroxy-5,10-dimethyl-3-oxo-2,14-dioxabicyclo[11.3.1]heptadeca-4,8-dien-15-yl]-2-thiazolidinone
- (4R)-4-[(1R,4Z,8Z,10S,13R,15R)-15-hydroxy-5,10-dimethyl-3-oxo-2,14-dioxabicyclo[11.3.1]heptadeca-4,8-dien-15-yl]thiazolidin-2-one
- (4S)-4-((1R,4Z,8Z,13R,15R)-15-hydroxy-5,10-dimethyl-3-oxo-2,14-dioxabicyclo(11.3.1)heptadeca-4,8-dien-15-yl)-1,3-thiazolidin-2-one
- 2-THIAZOLIDINONE, 4-((1R,4Z,8Z,10S,13R,15R)-15-HYDROXY-5,10-DIMETHYL-3-OXO-2,14-DIOXABICYCLO(11.3.1)HEPTADECA-4,8-DIEN-15-YL)-, (4R)-
- 2-THIAZOLIDINONE, 4-(15-HYDROXY-5,10-DIMETHYL-3-OXO-2,14-DIOXABICYCLO(11.3.1)HEPTADECA-4,8-DIEN-15-YL)-, (1R-(1R*,4Z,8Z,10S*,13R*,15R*(R*)))-
- 2-Thiazolidinone, 4-[(1R,4Z,8Z,10S,13R,15R)-15-hydroxy-5,10-dimethyl-3-oxo-2,14-dioxabicyclo[11.3.1]heptadeca-4,8-dien-15-yl]-, (4R)-
- 2-Thiazolidinone,4-[(1R,4Z,8Z,10S,13R,15R)-15-hydroxy-5,10-dimethyl-3-oxo-2,14-dioxabicyclo[11.3.1]heptadeca-4,8-dien-15-yl]-,(4R)-
- 4-((1R,4Z,8Z,10S,13R,15R)-15-hydroxy-5,10-dimethyl-3-oxo-2,14-dioxabicyclo(11.3.1)heptadeca-4,8-dien-15-yl)-1,3-thiazolidin-2-one
- 4-((1R,4Z,8Z,13R,15R)-15-hydroxy-5,10-dimethyl-3-oxo-2,14-dioxabicyclo(11.3.1)heptadeca-4,8-dien-15-yl)-1,3-thiazolidin-2-one
- Cytoskeleton-targeting compounds (glaucoma), Wisconsin Alumni Research Foundation (WARF)/Inspire
- LAB